Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination.
OBJECTIVE
To evaluate the role of serum antimullerian hormone (AMH) concentration in predicting live birth outcome in controlled ovarian stimulation and intrauterine insemination (IUI).


METHODS
Retrospective analysis.


METHODS
Tertiary assisted reproduction unit.


METHODS
243 patients undergoing IUI treatment.


METHODS
Archived early follicular phase serum samples taken at the start of the first treatment cycle before ovarian stimulation were retrieved from patients undergoing IUI treatment.


METHODS
First-cycle and cumulative live birth rates.


RESULTS
Patients attaining a successful live birth, either in the first cycle or cumulatively after three cycles, had significantly higher serum AMH concentrations than those failing treatment. Serum AMH concentration correlated positively with antral follicle count (AFC) and duration of stimulation and inversely with maternal age, serum FSH concentration, and total dose of gonadotropin used. After controlling for age, body mass index, AFC, and FSH, AMH remained the only significant predictor of cumulative live birth. The area under the receiver operating characteristic curve was 0.668 in predicting cumulative live birth. Serum AMH concentration was significantly higher in overresponders.


CONCLUSIONS
Serum AMH concentration was significantly higher in subjects with a live birth from the first cycle or after three cycles of stimulated IUI treatment compared with those failing treatment. Serum AMH concentration has a modest predictive value on ovarian overresponse.
Li
Hang Wun Raymond
HW
Centre of Assisted Reproduction and Embryology, Department of Obstetrics and Gynaecology, University of Hong Kong, Queen Mary Hospital, Hong Kong. raymondli@hkucc.hku.hk
Yeung
William Shu Biu
WS
Lau
Estella Yee Lan
EY
Ho
Pak Chung
PC
Ng
Ernest Hung Yu
EH
D000328:Adult; D054304:Anti-Mullerian Hormone / Q000032:analysis / Q000097:blood*; D004526:Efficiency; D005260:Female; D006801:Humans; D007246:Infertility / Q000097:blood / Q000175:diagnosis* / Q000628:therapy; D007315:Insemination, Artificial / Q000379:methods; D050498:Live Birth; D016471:Ovarian Hyperstimulation Syndrome / Q000175:diagnosis; D010062:Ovulation Induction / Q000009:adverse effects / Q000379:methods; D011237:Predictive Value of Tests; D011247:Pregnancy; D018873:Pregnancy Rate; D011379:Prognosis; D012189:Retrospective Studies; D014599:Uterus
D054304:Anti-Mullerian Hormone